I. General interferon, including Seroquin, Yundein, Intefin, Anfolon and dozens of varieties Note: more varieties, divided into alpha-2a and alpha-2b, etc., mostly domestic II. Long-acting interferon, including: Pyroxin (pegylated interferon alpha-2a) and Pellegrin (pegylated interferon alpha-2b) Indications: chronic hepatitis B, hepatitis B virus DNA-positive, cirrhosis patients are prohibited Dosage: 1 injection per week A course of treatment time: 0.5 to 1 year Note: Long-acting interferon has a variety of different dose specifications, are imported Three, lamivudine (heptyn) Indications: chronic hepatitis B, hepatitis B virus DNA-positive people, patients with cirrhosis can also be used Dosage: 1 tablet per day 100 mg A course of treatment time: at least 2 to 2.5 years Note: Variant resistance rate is high, once The drug resistance needs to be combined with Adefovir. IV. Tebivudine (Subivudine) Indications: chronic hepatitis B, hepatitis B virus DNA positive, patients with cirrhosis can also be used. Chronic hepatitis B, hepatitis B virus DNA-positive patients, patients with cirrhosis can also be used Dosage: 1 tablet per day 10 mg per tablet A course of treatment time: at least 2 to 2.5 years Note: There are several varieties of domestic and imported, prices vary Six, entecavir (Boludin) Indications: chronic hepatitis B, hepatitis B virus DNA-positive patients, patients with cirrhosis can also be used Dosage: 1 tablet per day 500 micrograms per tablet A course of treatment time: at least 2 to 2.5 years Note: When treating lamivudine mutants, you need to take 2 tablets daily Hepatitis B antiviral drugs vary slightly in price from place to place, and most are not reimbursed by medical insurance, which means that the majority of hepatitis B patients must fully consider their financial strength and affordability when deciding to undergo antiviral treatment, and should not be rushed into it just for the sake of the moment, and later be unable to adhere to it. The antiviral treatment needs to be adhered to for a long time and cannot just be abandoned halfway. Sudden discontinuation of the drug may trigger aggravation of the disease, especially with nucleoside analogues. Regular interferon has been used for many years to treat chronic hepatitis B. It is not as effective as long-acting interferon (pegylated interferon) but the adverse effects of the two drugs are similar, and patients have to face and overcome a variety of adverse effects throughout the treatment process: bone marrow suppression, fever, hair loss, etc. Most patients with chronic hepatitis B can only achieve sustained viral suppression with long-term nucleoside analogue therapy, because to achieve the desired therapeutic effects: sustained negative hepatitis B virus DNA, serological conversion of hepatitis B virus e antigen to e antibody, and consistently normal liver function, which cannot be achieved in a short period of time; the use of nucleoside analogues to treat patients with hepatitis B cirrhosis requires lifelong medication; treatment of Patients who are negative for hepatitis B virus e antigen need to be treated until the hepatitis B virus surface antigen is converted to negative. The use of nucleoside analogs for antiviral therapy may trigger the occurrence of hepatitis B virus mutation resistance, and once this occurs, the treatment regimen needs to be changed, and the change, whether it is a combination of drugs or a change to a better drug treatment, will mean an increase in treatment costs. “Doctors and patients need to make careful decisions and follow up regularly throughout the antiviral treatment process to prevent any untoward events.